Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis by Waschbisch, Anne et al.
Glatiramer Acetate Treatment Normalizes Deregulated
microRNA Expression in Relapsing Remitting Multiple
Sclerosis
Anne Waschbisch
1*, Monika Atiya
1, Ralf A. Linker
1, Sergej Potapov
2, Stefan Schwab
1, Tobias Derfuss
1,3
1Department of Neurology, Friedrich-Alexander University, Erlangen-Nu ¨rnberg, Germany, 2Institute of Medical Informatics, Biometry and Epidemiology, Friedrich-
Alexander University, Erlangen-Nu ¨rnberg, Germany, 3Department of Neurology, University Hospital Basel, Basel, Switzerland
Abstract
The expression of selected microRNAs (miRNAs) known to be involved in the regulation of immune responses was analyzed
in 74 patients with relapsing remitting multiple sclerosis (RRMS) and 32 healthy controls. Four miRNAs (miR-326, miR-155,
miR-146a, miR-142-3p) were aberrantly expressed in peripheral blood mononuclear cells from RRMS patients compared to
controls. Although expression of these selected miRNAs did not differ between treatment-naı ¨ve (n=36) and interferon-beta
treated RRMS patients (n=18), expression of miR-146a and miR-142-3p was significantly lower in glatiramer acetate (GA)
treated RRMS patients (n=20) suggesting that GA, at least in part, restores the expression of deregulated miRNAs in MS.
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Introduction
microRNAs (miRNAs) have recently emerged as potential
biomarkers of disease in different autoimmune disorders including
rheumatoid arthritis [1], systemic lupus erythematosus [2] or
Sjo ¨gren’s syndrome [3]. miRNAs are short (,22 nucleotides) non-
coding RNA molecules that regulate gene expression at the post-
transcriptional level. One miRNA may target several hundreds of
messenger RNAs and it has been proposed that up to 50% of
mammalian genes underlay miRNA fine-tuning [4]. miRNAs are
critically involved in the regulation of a wide array of cellular and
developmental processes including the differentiation of immune
cells and the outcome of immune responses [5].
Recent data indicate that miRNA dysregulation may also
contribute to the pathogenesis of multiple sclerosis (MS):
Overexpression of miRNAs that target CD47 was found to
contribute to macrophage-mediated damage in active MS lesions
and miRNA expression profiling in whole blood or leukocytes
derived from MS patients suggests an aberrant expression of
various miRNAs in the peripheral immune compartment [6,7].
Here we studied the expression of five selected immunologically
relevant miRNAs in peripheral blood mononuclear cells (PBMC)
derived from patients with relapsing-remitting multiple sclerosis
(RRMS) and healthy controls and addressed the impact of
immunomodulatory therapy on miRNA expression by comparing
treatment-naı ¨ve to glatiramer acetate (GA) or interferon-beta
(IFN-beta) treated patients.
Results
Overexpression of miR-142-3p, miR-155, miR-146a and
miR-326 in PBMC of RRMS Patients
We studied the expression of five selected miRNA (miR-20b,
miR-142-3p, miR-146a, miR-155 and miR-326) in PBMC derived
from treatment naı ¨ve patients with RRMS (n=36) and healthy
controls (HC, n=32). While no significant differences could be
detected for the expression of miR20b, the expression of miRNAs
miR-142-3p, miR-146a, miR-155 and miR-326 was remarkably
increased (between 2 and 3 fold) in untreated RRMS patients
compared to healthy controls (Figure 1). No significant correla-
tions were found between the expression of miRNA and age or
gender (data not shown). To analyze the diagnostic potential of
individual miRNAs to predict disease, we computed receiver
operator characteristic curves (ROC) for each miRNA based on
the data from treatment-naı ¨ve patients and healthy donors. The
discriminatory power of individual miRNA was low with an area
under the curve ranging from 0.67- 0.74. The ROC curves of
miR-326 and miR-142-3p are exemplary depicted (Figure 2). To
investigate whether a combination of any of these miRNAs may be
more accurate in predicting disease, a stepwise quadratic
discriminant analysis was performed and evaluated using the
leave-one-out cross-validation technique. The combination of
miR-155, miR-146a and miR-142-3p yielded the best results with
a sensitivity of 77.8% and a specificity of 88.0% in predicting
disease (AUC 0.77).
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Restored in GA Treated MS Patients
In parallel we analyzed the expression of miRNA in a group of
glatiramer acetate (n=20) and interferon-beta (n=18) treated
RRMS patients to detect a potential impact of immunomodulatory
therapy on deregulated miRNA. The expression of miR-142-3p,
miR-146a, miR-155, miR-326 and miR-20b did not differ between
treatment-naı ¨ve and IFN-beta treated RRMS patients. In contrast,
the expression of miR-142-3p and miR-146a was significantly
decreased in GA treated RRMS patients to values that resembled
the level of normal (p=0,003; p=0,028). miR-155 and miR-326
did not differ between untreated and the glatiramer acetate treated
group (Figure 1). In vitro stimulation of PBMC derived from
untreated MS patients with GA for up to 72 hours (40 mg/ml) did
not result in the downregulation of the miRNAs under investigation
suggesting that the effects of miRNA modulation by GA areof more
complex nature requiring long-term GA exposure or interaction
with resident cells of secondary lymphoid organs (Figure S1).
Discussion
Emerging evidence supports a critical role of miRNAs in the
pathogenesis of autoimmune diseases including multiple sclerosis
[5,6]. miRNA profiling studies in MS patients have repeatedly
demonstrated an aberrant expression of specific miRNA in cells of
the peripheral blood and deregulated miRNAs have been
proposed as diagnostic biomarkers of the disease [8-13]. However,
the results of these studies were contradictory which may be
secondary to patient selection (disease activity [13], immunomod-
ulatory treatment [11], inclusion of progressive MS [8], ethnic
origin [10]), sampling of different materials (whole blood [8,11],
leukocytes [13], lymphocyte subsets[9,10]) and differences in the
chosen screening method (microarray analysis[8,11], microfluidic
TaqMan arrays [12,13]). Accordingly, although several miRNAs
have been proposed as biomarkers in different states of the disease,
validation in a well-defined and homogenous population of
patients with RRMS is still required. Therefore we decided to
Figure 1. miRNA dysregulation in MS and the impact of immunomodulatory treatment. The relative expression of the mature miRNAs
miR-326, miR-155, miR-146a and miR-142-3p in PBMC derived from healthy donors (HD, n=32), treatment-naı ¨ve patients with RRMS (n=36) and
glatiramer acetate (GA, n=20) or Interferon-beta (IFN, n=18) was analyzed by real-time PCR. Bars represent the mean + S.E.M. * p,0,05; **p,0,005.
doi:10.1371/journal.pone.0024604.g001
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quantitative PCR in a cohort of treatment-naive RRMS patients
and healthy controls.
Two of the miRNAs found to be overexpressed in MS, miR-326
and miR-155 have recently been identified as crucial regulators of
T cell development and Th17 differentiation [10,14] and were
found to promote CNS inflammation in experimental autoim-
mune encephalomyelitis (EAE). The first-time demonstration of
miR-326 and miR-155 overexpression in PBMC derived from
European MS patients underlines the clinical significance of these
findings and adds to previous data on miR-326 dysregulation in
Chinese patients with relapsing MS [10].
While the expression levels of miR-326 and miR-155 did not
differ between untreated and GA or IFN-beta treated patients, GA
treatment seemed to normalize miR-146a and miR-142-3p
expression in MS patients. miR-142-3p expression has been
linked to immune tolerance, since it was found to be repressed by
FOXP3 resulting in an increased production of cyclic AMP and
suppressor function in T regulatory cells [15]. Here we
demonstrate upregulation of miR-142-3p in PBMC from RRMS
patients which is in line with a previous report [11]. The
mechanisms by which GA influences the expression of miR-142-
3p remain unknown. However, it is well perceivable that an
expansion of T regulatory cells by glatiramer acetate and/or
changes in the composition of the T cell compartment may
account for the downregulation of miR-142-3p.
miR-146a has emerged as a key player in the regulation of
innate immunity and seems to be critical for the suppressor
function of T regulatory cells [16]. miR-146a was found to be
overexpressed at the site of inflammation in RA [17], psoriasis [18]
and within active MS lesions [19]. We hypothesize that
overexpression of miR-146a in PBMC of MS patients is reactive
to the proinflammatory milieu in MS. In this light, downregulation
of miR-146a in the glatiramer acetate treatment group may reflect
restoration of the cytokine milieu by GA dependent induction of a
Th1 to Th2 shift and inhibition of monocyte reactivity [20–22].
There are certain possibleconfoundersto this study. The mean age
and disease duration was higher in GA and IFN treated patients
compared to treatment-naı ¨ve patients which is an obvious conse-
quence of an early treatment strategy. Since miRNA expression in
PBMC may change with age and immune senescence or may be
influenced by a chronic inflammatory state we analysed whether
expression of the studied miRNAs was biased by age or disease
duration. However, we did not find significant correlations of the
miRNA expression levels with age or disease duration in our study.
The patients we studied represent a rather active MS
population as reflected by the high percentage of patients that
experienced relapse within the last 3 months (up to 39% within the
no treatment group). It has been suggested that certain miRNAs
levels may increase during MS relapse [10,13]. Since recent MRI
as a surrogate marker of disease activity was not available in most
of the patients we cannot control a possible influence of disease
activity on miRNA expression in our study which may have biased
our results.
Summarizing, we report the aberrant expression of four
miRNAs, previously reported to be critically involved in TH17
differentiation (i.e. miR-326, miR-155), the regulation of immune
tolerance (miR-142-3p, miR-146a) or innate immunity (miR-
146a). Immunomodulatory treatment with IFN-beta did not
restore the expression of deregulated miRNAs, whereas GA
treatment seemed to normalize the levels of miR-146a and miR-
142-3p but not miR-155 and miR-326 expression in RRMS
patients. The biologic significance of our findings is further
underlined by the fact that the overexpressed miRNA in
peripheral blood leukocytes, were also among the most signifi-
cantly upregulated miRNAs in active MS lesions in a seminal
study by Junker et al. [19]. In conclusion, our study adds to the
emerging evidence of miRNA dysregulation in MS.
Figure 2. ROC analysis. To assess the sensitivity and specificity of miRNAs to predict disease, receiver operator characteristic curves were
computed based on the relative miRNA expression in treatment-naı ¨ve patients and healthy controls. The ROC curves for miR-326 and miR-142-3p are
exemplary depicted.
doi:10.1371/journal.pone.0024604.g002
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Patients and Sample Collections
The study was approved by the ethics committee of the
Friedrich-Alexander University Erlangen (No. 4203) and written
informed consent was obtained from all participants. RRMS
patients that had been diagnosed according to the McDonald
criteria were eligible for participation in this study. Patients had to
be either treatment naı ¨ve, or treated with the immunomodulatory
drugs glatiramer acetate (GA, CopaxoneH) or Interferon-beta
(IFN-beta, AvonexH n=5, RebifH n=8, BetaferonH n=5) for at
least 3 months. Patients that were treated with glucocorticoids
during the last four weeks before study entry were excluded from
the study. .97% of patients and healthy controls were of
Caucasian origin. All patients were assessed for EDSS and clinical
parameters of disease activity by their treating physician. Patients
that had been relapse-free for at least 3 months were considered as
clinically stable. Peripheral blood was obtained by venipuncture
and immediately processed for isolation of PBMCs. Demographic
and clinical details are summarized in table 1.
Isolation of PBMCs and RNA Isolation
PBMCs were isolated from EDTA blood via ficoll density
gradient centrifugation. 1610
7 cells were resuspended in QiazolH
(Qiagen, Hilden, Germany) and stored at 280uC. RNA enriched
in miRNA was isolated using the miRNAeasyH Mini and RNeasyH
MinEluteH Cleanup Kit according to the manufacturer’s protocol.
Total RNA concentrations were determined using a NanoDrop
spectrophotometer (NanoDrop technologies, USA).
In Vitro GA Stimulation of PBMC
PBMC were cultured in RPMI 1640 (Gibco Invitrogen GmbH,
Karlsruhe, Germany) supplemented with 10% of FCS (PAA,
Pasching, Austria), glutamine and antibiotics. Cells were grown at
a densitiy of 2610
6 ml in 6-well plates (Gibco Invitrogen GmbH,
Karlsruhe, Germany) under standard culture conditions (37uC,
5%CO2). GA (CopaxoneH,4 0mg/ml) was added to the medium
for different periods of time. RNA was isolated as described above.
Real-Time PCR
The TaqManH MicroRNA Reverse Transcription Kit was used
according to the manufacturer’s instruction for reverse transcrip-
tion with target specific stem loop primers provided in TaqManH
miRNA Assays. The TaqMan Universal MasterMix was used
according to the manufacturer’s protocol for amplification of the
targets on an ABI PRISMH 7900 HT Real Time PCR System.
The following TaqMan miRNA assays were used: hsa-miR-155,
Assay ID 002623; hsa-miR-326, Assay ID 000542; hsa-miR-142-
3p, Assay ID 000464; hsa-miR-146a, Assay ID 000468; has-miR-
20b, Assay ID 001014. RNU6B (Assay ID 001093) that has been
previously used in several studies analyzing miRNA expression in
immune cells
10–12 was used as an endogenous control to calculate
DCT. All samples were analysed in triplicates. The average DCT
of healthy donors was used as a calibrator to calculate DDCT.
Results are expressed as 2
-DDCT.
Statistical Analysis
Differences in miRNA expression were determined using
nonparametric tests (Mann-Whitney-U, Kruskal-Wallis-Test with
Dunn’s multiple comparison). p-values ,0.05 were considered
significant. Correlation of miRNA expression with age, disease
duration and gender was assessed by calculating the spearman and
point-biserial correlation coefficient. Receiver operator character-
istic curves (ROC) were computed and the area under the curve
(AUC) was calculated to assess the discriminatory power of
individual miRNA. A quadratic discriminant analysis (QDA) was
employed to assess the predictive power of a combination of
miRNAs to differentiate between healthy controls or RRMS
patients. The adapted model was evaluated by the leave-one-out
cross-validation method. Statistical analysis was performed using
the R-system for statistical computing [23] (version 2.12.2, R
Development Core Team 2011) and GraphPad Prism (version 5.0,
GraphPad Software Inc.).
Supporting Information
Figure S1 miRNA expression was analyzed in PBMC
derived from RRMS patients (n=6) after in vitro
treatment with glatiramer acetate (GA, 40 mg/ml) for
the indicated periods of time.
(TIF)
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Table 1. Clinical and demographic details of patients and healthy controls.
mean age +/-SD f:m ratio median EDSS EDSS range
. 3 months relapse
free
mean disease duration
+/2 SD
Healthy Controls 34.5 +/2 10.7 a 1.7:1 n/a n/a n/a n/a
treatment-naı ¨ve RRMS 36.6 +/2 9.6 a 2.0:1 1.5 0-3.5 61% 5.1 +/2 6.1 a
Glatiramer Acetate
{ treated
RRMS
40.5 +/2 12.3 a 1.9:1 1.75 0-4.0 75% 9.4 +/2 7.6 a
IFN-beta
{ treated RRMS 38.8 +/2 6.7 a 2.6:1 2 0-5.5 83.3% 8.8 +/2 7.8a
{CopaxoneH;
{AvonexH n=5, BetaferonH n=5, RebifH 22 n=4, RebifH 44 n=8; SD: standard deviation.
doi:10.1371/journal.pone.0024604.t001
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